216
Participants
Start Date
December 3, 2018
Primary Completion Date
September 6, 2023
Study Completion Date
October 31, 2023
FP-1305 (bexmarilimab)
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Turku University Hospital, Turku
START Madrid - CIOCC Hospital HM Sanchinarro, Madrid
Tampere University Hospital, Tampere
Oulu University Hospital, Oulu
The Institut Gustave Roussy, Villejuif
The University of Texas Health Science Center at San Antonio, San Antonio
Clinical Research Institute HUCH Ltd, Helsinki
Erasmus University Medical Center Rotterdam, Rotterdam
The Royal Marsden NHS Foundation Trust, Sutton
Queen Elizabeth Hospital Birmingham, Birmingham
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Faron Pharmaceuticals Ltd
INDUSTRY